Overview

SG1906 for CLDN18.2-Positive Solid Tumors

Status:
Recruiting

Trial end date:
2025-08-30

Target enrollment:

Participant gender:

Summary

This is a Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients with CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Hangzhou Sumgen Biotech Co., Ltd.